Sudden death forces Sophiris to halt followup therapy in prostate cancer study — shares crushed

Small-cap biotech Sophiris $SPHS has hit the brakes on its dosing schedule for patients in its Phase IIb prostate cancer study after one of the subjects in the trial died shortly after receiving a second dose.